

# IL CURRICULUM VITAE



## INFORMAZIONI PERSONALI

Nome	<b>TUBARO ANDREA</b>
Indirizzo	<b>VIA VAL PELLICE, 53 – 00141 ROMA</b>
Telefono	<b>06 3377 5469 / 7712 (ufficio) – 335 8185925 (cellulare)</b>
Fax	<b>06 3377 5059</b>
E-mail	<b>andrea.tubaro@mac.com</b>
Nazionalità	Italiana
Data di nascita	3 dicembre 1958

## ESPERIENZA LAVORATIVA

- Date (1 novembre 2010 - oggi)
    - Nome e indirizzo del datore di lavoro
    - Tipo di azienda o settore
    - Tipo di impiego
  - Principali mansioni e responsabilità
  - Date (1 novembre 2001 – 31 ottobre 2010)
    - Nome e indirizzo del datore di lavoro
    - Tipo di azienda o settore
    - Tipo di impiego
  - Principali mansioni e responsabilità
  - Date (1 novembre 2001 – oggi)
    - Nome e indirizzo del datore di lavoro
    - Tipo di azienda o settore
    - Tipo di impiego
  - Date (1 novembre 2000 – 31 ottobre 2001)
    - Nome e indirizzo del datore di lavoro
    - Tipo di azienda o settore
    - Tipo di impiego
  - Date (1 novembre 1988 – 31 ottobre 2000)
    - Nome e indirizzo del datore di lavoro
    - Tipo di azienda o settore
    - Tipo di impiego
- Dirigente di I° livello  
Azienda Ospedaliera Sant'Andrea, Via di Grottarossa 1035 – 00189 Roma  
Medicina  
Tempo pieno  
**RESPONSABILE U.O.C. DI UROLOGIA**
- Dirigente di II° livello  
Azienda Ospedaliera Sant'Andrea, Via di Grottarossa 1035 – 00189 Roma  
Medicina  
Tempo pieno  
**RESPONSABILE U.O.S. DI CHIRURGIA MININVASIVA**
- Professore Associato di Urologia  
2a Facoltà di Medicina e Chirurgia ora Facoltà di Medicina e Psicologia, Sapienza Università di Roma  
Università  
Tempo pieno
- Ricercatore confermato  
Facoltà di Medicina e Chirurgia, Università di L'Aquila  
Università  
Tempo pieno
- Tecnico Laureato (VIII° livello)  
Facoltà di Medicina e Chirurgia, Università di L'Aquila  
Università  
Tempo pieno

## ISTRUZIONE E FORMAZIONE

- Date (1994) Membro Board Europeo di Urologia
- Nome e tipo di istituto di istruzione o formazione European Board of Urology (EBU)
  - Principali materie / abilità professionali oggetto dello studio Urologia
  - Qualifica conseguita Riconoscimento della specializzazione da parte del Board Europeo di Urologia
- Date (1983 – 1988) Specializzazione in Urologia
- Nome e tipo di istituto di istruzione o formazione Sapienza Università di Roma
  - Principali materie / abilità professionali oggetto dello studio Urologia
  - Qualifica conseguita Specialista in Urologia
- Date (1984) Esame di Stato
- Nome e tipo di istituto di istruzione o formazione Ordine dei Medici di Roma
  - Principali materie / abilità professionali oggetto dello studio Medicina
  - Qualifica conseguita Abilitazione all'esercizio della professione medica
- Date (1983 -1988) Corso di Laurea in Medicina e Chirurgia
- Nome e tipo di istituto di istruzione o formazione Sapienza Università di Roma
  - Principali materie / abilità professionali oggetto dello studio Medicina
  - Qualifica conseguita Medico Chirurgo

MADRELINGUA	<b>ITALIANO</b>
ALTRE LINGUA	
<ul style="list-style-type: none"> <li>• Capacità di lettura</li> <li>• Capacità di scrittura</li> <li>• Capacità di espressione orale</li> </ul>	<b>INGLESE</b> ECCELLENTE ECCELLENTE ECCELLENTE
CAPACITÀ E COMPETENZE RELAZIONALI	COORDINAMENTO GRUPPI DI STUDIO E DI RICERCA SCIENTIFICA: - COMITATO IMAGING DELLA CONSULTAZIONE INTERNAZIONALE SULLA CONTINENZA, ANNI 2002, 2005, 2008, 2012 - Gruppi di ricerca diversi, come testimoniato dalla produzione scientifica allegata ed in particolare nei seguenti campi: immunoterapia locale dei tumori uroteliali, termoterapia transuretrale a microonde, diagnostica elettromagnetica dei tumori urologici.
CAPACITÀ E COMPETENZE ORGANIZZATIVE	- DIREZIONE DI UNITÀ OPERATIVA COMPLESSA - PARTECIPAZIONE AL CONSIGLIO DI AMMINISTRAZIONE DI SOCIETÀ SCIENTIFICHE: SOCIETÀ EUROPEA DI UROLOGIA, SOCIETÀ ITALIANA DI UROLOGIA, SOCIETÀ ITALIANA DI URODINAMICA. - PARTECIPAZIONE AL COMITATO ESECUTIVO DI SOCIETÀ SCIENTIFICHE: SOCIETÀ ITALIANA DI UROLOGIA - FONDAZIONE DEL UFFICIO PER LA RICERCA CLINICA DELLA SOCIETÀ EUROPEA DI UROLOGIA
CAPACITÀ E COMPETENZE TECNICHE	UTILIZZO PACCHETTI INFORMATICI WINDOWS, MAC OS X, OFFICE, SPSS
ALTRE CAPACITÀ E COMPETENZE	ATTIVITÀ DI RICERCA COME TESTIMONIATO DALLA ALLEGATA PRODUZIONE SCIENTIFICA COMPRENDENTE: - 149 PUBBLICAZIONE RECENSITE SU MEDLINE - 5 libri a stampa - 15 capitoli di libri
PATENTE O PATENTI	Patente di guida B

**ARTICOLI SCIENTIFICI SU RIVISTE  
RECENSITE IN MEDLINE**

1. Tubaro A, Puccini F, De Nunzio C, et al. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. *Curr Urol Rep*. Oct 2012;13(5):335-342.
2. Tubaro A. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. *BJU international*. May 2012;109(10):1517.
3. Tubaro A. Acute Urinary Retention Increases the Risk of Complications after Transurethral Resection of the Prostate: A Population-Based Study. *BJU international*. Oct 4 2012.
4. Tubaro A. Chronic Urinary Retention in Men: Can We Define It, and Does It Affect Treatment Outcome. *BJU international*. Mar 27 2012.
5. Pelin M, Sosa S, Della Loggia R, et al. The cytotoxic effect of palytoxin on Caco-2 cells hinders their use for in vitro absorption studies. *Food Chem Toxicol*. Feb 2012;50(2):206-211.
6. Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. *World J Urol*. Sep 28 2012.
7. Lucas MG, Bosch RJ, Burkhard FC, et al. EAU Guidelines on Surgical Treatment of Urinary Incontinence. *European urology*. Sep 17 2012.
8. Lucas MG, Bosch RJ, Burkhard FC, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. *European urology*. Aug 31 2012.
9. Leonardo C, Franco G, De Nunzio C, et al. Salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer. *Urology*. Jul 2012;80(1):130-133.
10. Leonardo C, De Nunzio C, Michetti P, et al. Plication corporoplasty versus Nesbit operation for the correction of congenital penile curvature. A long-term follow-up. *International urology and nephrology*. Feb 2012;44(1):55-60.
11. De Sio M, Yakoubi R, De Nunzio C, et al. Reporting quality of abstracts presented at the European association of urology meeting: a critical assessment. *The Journal of urology*. Nov 2012;188(5):1883-1886.
12. De Nunzio C, Tubaro A. BPH: unmet needs in managing LUTS--a European perspective. *Nat Rev Urol*. Jan 2012;9(1):9-10.
13. De Nunzio C, Leonardo C, Franco G, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. *World J Urol*. May 11 2012.
14. Cotterill N, Goldman H, Kelleher C, Kopp Z, Tubaro A, Brubaker L. What are the best outcome measures when assessing treatments for LUTD?--achieving the most out of outcome evaluation: ICI-RS 2011. *Neurourology and urodynamics*. Mar 2012;31(3):400-403.
15. Cornu JN, Abrams P, Chapple CR, et al. A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management--a Systematic Review and Meta-analysis. *European urology*. Nov 2012;62(5):877-890.
16. Cicione A, Cantiello F, De Nunzio C, Tubaro A, Damiano R. Prostate biopsy quality is independent of needle size: a randomized single-center prospective study. *Urologia internationalis*. 2012;89(1):57-60.
17. Bove P, Lacovelli V, De Nunzio C, et al. Critical review of laparoendoscopic single-site surgery versus multiport laparoscopy in urology. *Arch Esp Urol*. Apr 2012;65(3):348-356.
18. Banez LL, Albisinni S, Freedland SJ, Tubaro A, De Nunzio C. The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. *World J Urol*. Jul 31 2012.
19. Apostolidis A, de Nunzio C, Tubaro A. What determines whether a patient with LUTS seeks treatment? ICI-RS 2011. *Neurourology and urodynamics*. Mar 2012;31(3):365-369.
20. Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. *Urology*. Jul 2012;80(1):162-167.
21. Albisinni S, De Nunzio C, Tubaro A. Pure small cell carcinoma of the

- prostate: A rare tumor. *Indian J Urol*. Jan 2012;28(1):89-91.
22. Tubaro A, Koelbl H, Laterza R, Khullar V, de Nunzio C. Ultrasound imaging of the pelvic floor: where are we going? *Neurourology and urodynamics*. Jun 2011;30(5):729-734.
  23. Tubaro A, De Nunzio C. Words of wisdom. Re: Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *European urology*. Nov 2011;60(5):1120-1121.
  24. Tubaro A, De Nunzio C. Editorial comment. *Urology*. Oct 2011;78(4):935-936; author reply 936.
  25. Tubaro A. Assessment of Lower Urinary Tract Symptoms in Men by International Prostate Symptom Score and Core Lower Urinary Tract Symptom Score. *BJU international*. Aug 26 2011.
  26. Thuroff JW, Abrams P, Andersson KE, et al. [EAU Guidelines on Urinary Incontinence]. *Actas Urol Esp*. Jul-Aug 2011;35(7):373-388.
  27. Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. *European urology*. Mar 2011;59(3):387-400.
  28. Staskin D, Tubaro A, Norton PA, Ashton-Miller JA. Mechanisms of continence and surgical cure in female and male SUI: surgical research initiatives. *Neurourology and urodynamics*. Jun 2011;30(5):704-707.
  29. Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. *BJU international*. Mar 2011;107(6):946-954.
  30. Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family history on prostate cancer risk: implications for clinical management. *BJU international*. Mar 2011;107(5):716-721.
  31. Leonardo C, De Nunzio C, Michetti P, et al. Plication corporoplasty versus Nesbit operation for the correction of congenital penile curvature. A long-term follow-up. *International urology and nephrology*. May 11 2011.
  32. Laterza RM, De Gennaro M, Tubaro A, Koelbl H. Female pelvic congenital malformations. Part I: embryology, anatomy and surgical treatment. *Eur J Obstet Gynecol*. 2011.
  33. Laterza RM, De Gennaro M, Tubaro A, Koelbl H. Female pelvic congenital malformations. Part II: sexuality, reproductive outcomes and psychological impact. *Eur J Obstet Gynecol*. 2011.
  34. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. *European urology*. Jul 2011;60(1):106-117.
  35. De Nunzio C, Freedland SJ, Miano R, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. *Prostate*. Feb 25 2011.
  36. De Nunzio C, Freedland SJ, Miano L, Finazzi Agro E, Banez L, Tubaro A. The uncertain relationship between obesity and prostate cancer: An Italian biopsy cohort analysis. *Eur J Surg Oncol*. Dec 2011;37(12):1025-1029.
  37. De Nunzio C, Cicione A, Leonardo F, et al. Extraperitoneal radical cystectomy and ureterocutaneostomy in octogenarians. *International urology and nephrology*. Sep 2011;43(3):663-667.
  38. De Nunzio C, Carluccini A, Cicione A, et al. Prostate Cancer Does Not Influence Androgen Levels: A Radical Prostatectomy Cohort Study. *Urol Int*. Jan 21 2011.
  39. De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with early single Mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. *World J Urol*. Aug 2011;29(4):517-521.
  40. De Nunzio C, Albisinni S, Freedland SJ, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. *Urol Oncol*. Sep 16 2011.
  41. Cindolo L, De Nunzio C, Sountoulides P, Bantis A, Tubaro A, Schips L. The influence of ejaculation and abstinence on urinary flow rates.

- Neurourology and urodynamics*. Nov 2011;30(8):1571-1575.
42. Chu DI, De Nunzio C, Gerber L, et al. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. *Prostate Cancer Prostatic Dis*. Dec 2011;14(4):346-353.
  43. Brookman-May S, May M, Zigeuner R, et al. Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma. *The Journal of urology*. Dec 2011;186(6):2175-2181.
  44. Athanasopoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. *European urology*. Jul 2011;60(1):94-105.
  45. Tubaro A, Mariani S, De Nunzio C, Miano R. Bladder weight and detrusor thickness as parameters of progression of benign prostatic hyperplasia. *Curr Opin Urol*. Jan 2010;20(1):37-42.
  46. Tubaro A, De Nunzio C, Mariani S, et al. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. *Urology*. Aug 2010;76(2):436-441.
  47. Thuroff JW, Abrams P, Andersson KE, et al. EAU Guidelines on Urinary Incontinence. *Eur Urol*. Nov 24 2010.
  48. Miano R, Scoffone C, De Nunzio C, et al. Position: Prone or Supine Is the Issue of Percutaneous Nephrolithotomy. *J Endourol*. Mar 26 2010.
  49. Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family history on prostate cancer risk: implications for clinical management. *BJU Int*. Dec 16 2010.
  50. Kirby MG, Wagg A, Cardozo L, et al. Overactive Bladder: Is There a Link to the Metabolic Syndrome in Men? *Neurorol Urodyn*. Jun 29 2010.
  51. Franco G, De Nunzio C, Leonardo C, et al. Ultrasound assessment of intravesical prostatic protrusion and detrusor wall thickness--new standards for noninvasive bladder outlet obstruction diagnosis? *J Urol*. Jun 2010;183(6):2270-2274.
  52. De Nunzio C, Miano R, Trucchi A, et al. Photoselective prostatic vaporization for bladder outlet obstruction: 12-month evaluation of storage and voiding symptoms. *J Urol*. Mar 2010;183(3):1098-1103.
  53. De Gennaro M, Niero M, Capitanucci ML, et al. Validity of the international consultation on incontinence questionnaire-pediatric lower urinary tract symptoms: a screening questionnaire for children. *J Urol*. Oct 2010;184(4 Suppl):1662-1667.
  54. de Boer TA, Salvatore S, Cardozo L, et al. Pelvic organ prolapse and overactive bladder. *Neurorol Urodyn*. 2010;29(1):30-39.
  55. D'Eliseo D, Pisu P, Romano C, et al. Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. *Int J Cancer*. Sep 1 2010;127(6):1283-1294.
  56. Bright E, Oelke M, Tubaro A, Abrams P. Ultrasound Estimated Bladder Weight and Measurement of Bladder Wall Thickness--Useful Noninvasive Methods for Assessing the Lower Urinary Tract? *J Urol*. Sep 15 2010.
  57. Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurorol Urodyn*. 2010;29(1):213-240.
  58. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. *BJU Int*. Apr 2009;103 Suppl 3:33-41.
  59. Suardi N, Gallina A, Salonia A, et al. Open prostatectomy and the evolution of HoLEP in the management of benign prostatic hyperplasia. *Minerva Urol Nefrol*. Sep 2009;61(3):301-308.
  60. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. *BJU Int*. Apr 2009;103 Suppl 3:12-23.
  61. McVary K, Tubaro A, De Nunzio C. The Motion: PDE5 Inhibitors are a Promising Therapy for Benign Prostatic Hyperplasia. *Eur Urol*. Jul 31

- 2009.
62. De Nunzio C, Trucchi A, Miano R, et al. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. *J Urol.* Mar 2009;181(3):1069-1074; discussion 1074-1065.
  63. D'Eliseo D, Pisu P, Romano C, et al. Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. *Int J Cancer.* Dec 21 2009.
  64. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. *BJU Int.* Apr 2009;103 Suppl 3:4-11.
  65. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. *BJU Int.* Mar 5 2009.
  66. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. *Eur Urol.* Apr 2009;55(4):864-873.
  67. Tubaro A, De Nunzio C, Trucchi A, Stoppacciaro A, Miano L. The Electromagnetic Detection of Prostatic Cancer: Evaluation of Diagnostic Accuracy. *Urology.* Mar 10 2008;72:5.
  68. Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A. Treatment options for benign prostatic hyperplasia in older men. *Med Sci Monit.* Jul 2008;14(7):RA94-102.
  69. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. *BJU Int.* Jul 2008;102(1):56-61.
  70. Iori F, Franco G, Leonardo C, et al. Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. *Urology.* Feb 2008;71(2):252-255.
  71. De Nunzio C, Miano R, Trucchi A, Finazzi Agro E, Tubaro A. Finasteride for prostatic disease: an updated and comprehensive review. *Expert Opin Drug Metab Toxicol.* Dec 2008;4(12):1561-1568.
  72. van Adelsberg J, Gann P, Ko AT, et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. *Curr Med Res Opin.* Sep 2007;23(9):2063-2070.
  73. Tubaro A, De Nunzio C, Miano R. Transurethral needle ablation of the prostate. *Curr Opin Urol.* Jan 2007;17(1):7-11.
  74. Tubaro A. Testosterone and prostate cancer. *Eur Urol.* Feb 2007;51(2):293-295.
  75. Scarpa RM, Carrieri G, Gussoni G, et al. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. *Eur Urol.* Jan 2007;51(1):130-135; discussion 136.
  76. Keane T, Gillatt D, Evans CP, Tubaro A. Current and Future Trends in the Treatment of Renal Cancer. *European Urology Supplements.* 2007;6(3):11.
  77. Gravina GL, Costa AM, Galatioto GP, Ronchi P, Tubaro A, Vicentini C. Urodynamic obstruction in women with stress urinary incontinence--do nonintubated uroflowmetry and symptoms aid diagnosis? *J Urol.* Sep 2007;178(3 Pt 1):959-963; discussion 963-954.
  78. Gacci M, Del Popolo G, Artibani W, et al. Visual assessment of uroflowmetry curves: description and interpretation by urodynamicists. *World J Urol.* Jun 2007;25(3):333-337.
  79. Evans CP, Debruyne FMJ, Payne H, Solsona E, Teillac P, Tubaro A. Bladder Cancer: Management and Future Directions. *European Urology Supplements.* 2007;6(3):9.
  80. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. *Eur Urol.* Oct 2007;52(4):1204-1212.
  81. Tubaro A, Zattoni F, Prezioso D, et al. Italian validation of the International Consultation on Incontinence Questionnaires. *BJU Int.* Jan 2006;97(1):101-108.
  82. Tubaro A, Batista JE, Berges R, et al. Future Directions in Evaluating Nocturia and Its Impact in Patients with LUTS/BPH. *European Urology*

- Supplements*. 2006;5(1):3.
83. Tubaro A. Micronutrients and BPH. *Eur Urol*. Sep 2006;50(3):413-415.
  84. Tubaro A. BPH treatment: a paradigm shift. *Eur Urol*. Jun 2006;49(6):939-941.
  85. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. *Clin Genitourin Cancer*. Mar 2006;4(4):257-262.
  86. Roehrborn CG, Lotan Y, Tubaro A, de Nunzio C. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. *Eur Urol*. Feb 2006;49(2):396-400.
  87. Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. *European urology*. Sep 2006;50(3):563-568.
  88. De Gennaro M, Capitanucci ML, Di Ciommo V, et al. Reliability of bladder volume measurement with BladderScan in paediatric patients. *Scand J Urol Nephrol*. 2006;40(5):370-375.
  89. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. *Urology*. Aug 2006;68(2 Suppl):9-16.
  90. Chartier-Kastler E, Tubaro A. The Measurement of Nocturia and Its Impact on Quality of Sleep and Quality of Life in LUTS/BPH. *European Urology Supplements*. 2006;5(1):9.
  91. Chapple CR, Batista JE, Berges R, et al. The Impact of Nocturia in Patients with LUTS/BPH: Need for New Recommendations. *European Urology Supplements*. 2006;5(1):7.
  92. Artibani W, Pesce F, Prezioso D, et al. Italian validation of the urogenital distress inventory and its application in LUTS patients. *Eur Urol*. Dec 2006;50(6):1323-1329.
  93. Acquadro C, Kopp Z, Coyne KS, et al. Translating overactive bladder questionnaires in 14 languages. *Urology*. Mar 2006;67(3):536-540.
  94. Tubaro A, Palleschi G. Overactive bladder: epidemiology and social impact. *Curr Opin Obstet Gynecol*. Oct 2005;17(5):507-511.
  95. Tubaro A, De Nunzio C, Trucchi A, Palleschi G, Miano L. The effect of bladder outlet obstruction treatment on ultrasound-determined bladder wall thickness. *Rev Urol*. 2005;7 Suppl 6:S35-42.
  96. Trucchi A, De Nunzio C, Mariani S, Palleschi G, Miano L, Tubaro A. Local anesthesia reduces pain associated with transrectal prostatic biopsy. A prospective randomized study. *Urol Int*. 2005;74(3):209-213.
  97. Speakman M, Batista J, Berges R, et al. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise. *Prostate Cancer Prostatic Dis*. 2005;8(4):369-374.
  98. Palleschi G, Tubaro A, Miano L. [Overactive bladder: modulating the effects of antimuscarinic therapy]. *Minerva Urol Nefrol*. Dec 2005;57(4):237-245.
  99. Ockrim J, Laniado ME, Khoubehi B, et al. Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. *BJU Int*. Mar 2005;95(4):587-590.
  100. Lowe FC, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. *Prostate Cancer Prostatic Dis*. 2005;8(3):206-209.
  101. De Nunzio C, Franco G, Leonardo C, Trucchi A, Tubaro A, Laurenti C. Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uflowmetry evaluation. *Clin Drug Investig*. 2005;25(6):359-365.
  102. Bellorofonte C, Vedruccio C, Tombolini P, Ruoppolo M, Tubaro A. Non-invasive detection of prostate cancer by electromagnetic interaction. *Eur Urol*. Jan 2005;47(1):29-37; discussion 37.
  103. Vicentini C, Gravina GL, Angelucci A, et al. Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer



- from benign prostatic hyperplasia. *J Cancer Res Clin Oncol*. Apr 2004;130(4):217-221.
104. Tubaro A, La Vecchia C. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. *Eur Urol*. Jun 2004;45(6):767-772.
  105. Tubaro A, De Nunzio C. Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. *Eur Urol* 2003;44:512-8. *Eur Urol*. May 2004;45(5):674; author reply 674-675.
  106. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. *Urology*. Dec 2004;64(6 Suppl 1):2-6.
  107. Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter SS. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. *BJU Int*. Dec 2004;94(9):1283-1286.
  108. Carbone A, Palleschi G, Ciavarella S, et al. Experience with a bone anchor sling for treating female stress urinary incontinence: outcome at 30 months. *BJU Int*. Apr 2004;93(6):780-788.
  109. Tubaro A, Trucchi A, Miano L. Investigation of benign prostatic hyperplasia. *Curr Opin Urol*. Jan 2003;13(1):17-22.
  110. Tubaro A, Carter S, Trucchi A, Punzo G, Petta S, Miano L. Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage. *Drugs Aging*. 2003;20(3):185-195.
  111. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. *Urology*. Feb 2003;61(2):267-273.
  112. Vicentini C, Festuccia C, Angelucci A, et al. Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. *Anticancer Res*. Sep-Oct 2002;22(5):2917-2922.
  113. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. *Eur Urol*. Oct 2002;42(4):323-328.
  114. Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E. Sexual function in patients with LUTS suggestive of BPH. *European Urology Supplements*. 2001;40 Suppl 1:19-22.
  115. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. *The Journal of urology*. Jul 2001;166(1):172-176.
  116. Ockrim JL, Laniado ME, Patel A, Tubaro A, St Clair Carter S. A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. *J Urol*. Dec 2001;166(6):2221-2225.
  117. Tubaro A, Vicentini C, Renzetti R, Miano L. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials? *European Urology Supplements*. 2000;38 Suppl 1:7-17.
  118. Tubaro A, Miano L. Managing the Consequences of Obstruction. *European Urology Supplements*. 2000;1:7.
  119. Carter S, Tubaro A. Relation between intraprostatic temperature and clinical outcome in microwave thermotherapy. *J Endourol*. Oct 2000;14(8):617-625.
  120. Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is treated and how? *Eur Urol*. 1999;36 Suppl 3:28-32.
  121. Tubaro A. The use of voiding studies (flowmetry and urodynamics) in the assessment and follow-up of patients. *Curr Opin Urol*. Jan 1999;9(1):15-20.
  122. Scattoni V, Raber M, Montorsi F, et al. Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia. *European urology*. Dec 1999;36(6):621-630.

123. Tubaro A, d'Ancona FC. Case selection for high-energy transurethral microwave thermotherapy. *World J Urol.* 1998;16(2):124-130.
124. Russo F, Marinaro A, Sebastiani G, et al. [The Studer orthotopic ileal neobladder: patient compliance]. *Arch Ital Urol Androl.* Jun 1998;70(3 Suppl):47-53.
125. Russo F, Di Pasquale B, Romano G, et al. [International prostate symptom score: comparison of doctor and patient]. *Arch Ital Urol Androl.* Jun 1998;70(3 Suppl):15-24.
126. Manieri C, Carter SS, Romano G, Trucchi A, Valenti M, Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. *J Urol.* Mar 1998;159(3):761-765.
127. Hofner K, Tubaro A, de la Rosette JJ, Carter SS. Analysis of outcome after thermotherapy using different classifications of bladder outlet obstruction. *Neurourol Urodyn.* 1998;17(2):109-120.
128. Trucchi A, Franco G, Manieri C, Valenti M, Carter SS, Tubaro A. Manual versus computer methods for diagnosing obstruction from pressure-flow tracings in patients with benign prostatic hyperplasia. *J Urol.* Mar 1997;157(3):871-875.
129. de la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A. High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group. *J Urol.* Jul 1996;156(1):97-101; discussion 101-102.
130. de la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A. Pressure-flow study analyses in patients treated with high energy thermotherapy. *J Urol.* Oct 1996;156(4):1428-1433.
131. Tubaro A, Stoppacciaro A, Velotti F, et al. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. *Eur Urol.* 1995;28(4):297-303.
132. Tubaro A, Carter SSC, de la Rosette J, Hofner K, Miano L. Transurethral microwave heating, current status and future perspectives. *J Urol (Paris).* 1995;101(1):29-32.
133. Tubaro A, Carter SS, de la Rosette J, et al. The prediction of clinical outcome from transurethral microwave thermotherapy by pressure-flow analysis: a European multicenter study. *J Urol.* May 1995;153(5):1526-1530.
134. de Wildt MJ, Tubaro A, Hofner K, Carter SS, de la Rosette JJ, Devonec M. Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis. *J Urol.* Nov 1995;154(5):1775-1778.
135. de la Rosette JJ, Tubaro A, Trucchi A, Carter SS, Hofner K. Changes in pressure-flow parameters in patients treated with transurethral microwave thermotherapy. *J Urol.* Oct 1995;154(4):1382-1385.
136. de la Rosette JJ, Tubaro A, Hofner K, Carter SS. Transurethral microwave thermotherapy: past, present and future. *World J Urol.* 1994;12(6):352-356.
137. Tubaro A, Paradiso Galatioto G, Trucchi A, Miano L. [Transurethral thermotherapy by microwaves in patients with benign obstructive prostatic hypertrophy]. *J Urol (Paris).* 1993;99(6):338-343.
138. Tubaro A, Paradiso Galatioto G, Trucchi A, et al. Transurethral microwave thermotherapy in the treatment of symptomatic benign prostatic hyperplasia. *Eur Urol.* 1993;23(2):285-291.
139. Bologna M, Vicentini C, Corrao G, et al. Early diagnosis of prostatic carcinoma may be achieved through in vitro culture of tumor cells harvested by prostatic massage. *Eur Urol.* 1993;24(1):148-155.
140. Velotti F, Giuffrida A, Cippitelli M, et al. Soluble and cell-associated IL-2 receptor (IL-2R) after local immunotherapy with recombinant interleukin-2 (rIL-2). *Pharmacol. Res.* 1992;26(Suppl. 2):2.
141. Velotti F, Stoppacciaro A, Ruco L, et al. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2. *Cancer Res.* May 1 1991;51(9):2456-2462.
142. Tubaro A, Velotti F, Stoppacciaro A, et al. Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer.

- A phase IB study. *Cancer*. Jul 1 1991;68(1):56-61.
143. Miano L, Vicentini C, Manieri C, Tubaro A, Galatioto GP. The Studer-Zingg ileal-neobladder: the "ideal" bladder substitute? *Prog Clin Biol Res*. 1991;370:67-68.
  144. Velotti F, Tubaro A, Stoppacciaro A, et al. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study. *Ann Ist Super Sanita*. 1990;26(3-4):411-421.
  145. Miano L, Goldoni S, Tubaro A, Paradiso Galatioto G, Gandolfi P. Review of norfloxacin in lower urinary tract infections. *European Urology Supplements*. 1990;17 Suppl 1:13-18.
  146. Beomonte Zobel B, Vicentini C, Masciocchi C, et al. Magnetic resonance imaging in the localization of undescended abdominal testes. *Eur Urol*. 1990;17(2):145-148.
  147. Goldoni S, Gandolfi P, Tubaro A, Vicentini C, Lancione P, Miano L. Evaluation of the efficacy and safety of imipenem/cilastatin in the treatment of complicated urinary tract infections. *J Chemother*. Jul 1989;1(4 Suppl):845-847.
  148. Petta S, Tubaro A. [Clinico-diagnostic approach to the patient with erection disorders]. *Clin Ter*. Jul 31 1984;110(2):169-171.
  149. Perugia G, Petta S, Tubaro A, et al. [Transrectal prostatic cytology using needle aspiration. Review of 832 cases]. *Minerva Urol Nefrol*. Jan-Mar 1984;36(1):5-8.

## LIBRI

- 1) Current Therapy of Benign Prostatic Hyperplasia. C. Chapple and A. Tubaro. Eds. Martin Dunitz Ltd., Londra, 2000;
- 2) Urodinamica Clinica, Volume 1 - Tecnica. P. Di Benedetto, F. Pesce, Tubaro A. Eds., McGraw-Hill, Milano, 2003;
- 3) Urodinamica Clinica, Volume 2 - Indicazioni. P. Di Benedetto, F. Pesce, Tubaro A. Eds., McGraw-Hill, Milano, 2005;
- 4) Iperplasia Prostatica Benigna – Orientamento Diagnostico, Andrea Tubaro, Carocci Editore, Roma, 2011
- 5) Iperplasia Prostatica Benigna – Orientamento Terapeutico, Andrea Tubaro, Carocci Editore, Roma, 2011

## CAPITOLI DI LIBRI

- 1) A placebo-controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis. Preliminary results. Miano L, Petta S, Paradiso Galatioto G, Goldoni S, Tubaro A. In: Urolithiasis and Related Clinical Research. Schwille PO, Smith LH, Robertson WG, Vahlensieck W. Eds. Plenum Publishing Corporation, pp: 521-524, 1985.
- 2) Malattie dell'apparato urinario di interesse chirurgico. Miano L, Galassi P, Goldoni S, Manieri C, Paradiso Galatioto G, Tubaro A, Vicentini C. In: Trattato Italiano di Medicina Interna. P. Introzzi Ed., pp: 505.544, 1988.
- 3) The Studer-Zingg ileal neobladder: the "ideal" bladder substitute? Miano L, Vicentini C, Manieri C, Tubaro A, Paradiso Galatioto G, In: EORTC GU Group Monograph 10; Reconstructive Surgery, Organ Conservation, and Function restoration in Urological Oncology. PH Smith ed., New York, J Wiley and Sons, Inc. 1990.
- 4) Local Immunotherapy on human bladder cancer with recombinant IL-2: activation of immune response and possible direct effect action of IL-2 on tumour cells. Velotti F, Cippitelli M, Giuffrida AM, Punturieri A, Moretti F, Stoppacciaro A, Tubaro A, De Maria R, and Santoni A. In: Cytokine-induced tumour immunogenicity. Academic Press, 1994, pp: 429-442.

- 5) "Analisi della ricerca urologica", "Apparecchi di urodinamica: guida per una scelta oculata", "Apparecchiature ad alta tecnologia", "Gli stent ureterali", "L'urologo e l'aggiornamento". A Tubaro, In: L'Urologo Italiano, L. Miano, Ed., Hippocrates Ed., 1998, pp: 129-132; 161-171; 199-221.
- 6) Open Prostatectomy. A. Tubaro, In: Current Therapy for Benign Prostatic Hyperplasia. Martin Dunitz., Ltd. London 2000.
- 7) The Urodynamics of LUTS. Abrams P, Griffiths D, Hoefner K, Nishizawa O, Schefer W, Tubaro A, Zimmern PE, In: Benign Prostatic Hyperplasia. C. Chatelain, L. Denis, KT Foo, S. Khoury, J. McConnell, Eds. Health Publications Ltd. Plymouth (UK), 2001: pp: 227-281.
- 8) Imaging and Other Investigations: Artibani W, Anderson JT, Gajewski JB, Ostergard DR, Raz S, Tubaro A, In: Incontinence, P. Abrams, L. Cardozo, S. Khoury, A. Wein, Eds. Health Publication Ltd. Plymouth (UK), 2002, pp: 425-477.
- 9) Imaging and Other Investigations. Tubaro A, Artibani W, Bartram C, Dietz HP, Khullar V, DeLancey JD, Zimmern PE, In: Incontinence. P. Abrams, L. Cardozo, S. Khoury, A. Wein, Eds. Health Publication Ltd. Plymouth (UK), 2005, pp: 707-797. ISBN 0-9546956-2-3.
- 10) Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia: what is the evidence for rational diagnosis? A. Tubaro, C. De Nunzio, A. Trucchi. In: The Evidence for Urology. Chris Dawson & Gordon Muir Eds. tfm Publishing Ltd., Shrewsbury (UK) 2005, pp: 89-96.
- 11) LUTS: Etiology and Patient Assessment. P. Abrams, C. D'Ancona, K.T. Foo, D. Griffiths, O. Nishizawa, V. Nitti, A. Tubaro, P. van Kerrebroeck, A. Wein. In: Male Lower urinary Tract Dysfunction. J. McConnell, P. Abrams, L. Denis. S. Khoury, C. Roehrborn, Eds. Health Publications Ltd. 2006, ISBN 0-9546956-6-6, pp: 69-142.
- 12) Radiological Imaging. Tubaro A, Carbone A, Trucchi A. in: Textbook of female Urology and Urogynecology. Linda Cardozo and David Staskin Eds. Informa Healthcare, 2006, Oxon (UK), pp 339-353.
- 13) Imaging, Neurophysiology and Other Investigations. A. Tubaro, G. Amarenco, W. Artibani, C. Bartram, M. De Gennaro. J. De Lancey, V. Khullar, K. Kluivers, S. Podnar, M. Vierhout, D. Vodusek. In: Incontinence, Paul Abrams, Linda Cardozo, Alan Wien, Eds., Health Publication Ltd, 2009, pp: 485 - 517.
- 14) Bladder Ultrasound in Voiding Dysfunction. A Tubaro and M. De Gennaro. In: Atlas of Bladder Disease. D. Stakin Ed. Springer, Philadelphia, 2010, pp: 81-96.
- 15) Imaging of the Lower Urinary Tract (radiology and ultrasound). Tubaro A, Carbone A, Trucchi A. in: Textbook of female Urology and Urogynecology. Third Edition. Linda Cardozo and David Staskin Eds. Informa Healthcare, 2010, Oxon (UK), Chapter 36.

*Andrea Tubaro*

Prof. Andrea Tubaro

Roma, 30 novembre 2012